Showing 1 - 7 results of 7 for search 'Lynda J Krasenbaum', query time: 0.03s Refine Results
  1. 1
    A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

    A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States by Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen, Maurice T. Driessen

    Published 2022-05-01
    Get full text
    Article
  2. 2
    Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study

    Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective ch... by Hsiangkuo Yuan, Fred Cohen, Maurice T Driessen, Lynda J Krasenbaum, Mario Ortega, Mary Hopkins, Michael J Marmura

    Published 2024-03-01
    Get full text
    Article
  3. 3
    Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments

    Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments by George R. Nissan, Richard Kim, Joshua M. Cohen, Michael J. Seminerio, Lynda J. Krasenbaum, Karen Carr, Vincent Martin

    Published 2022-07-01
    Get full text
    Article
  4. 4
    Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine

    Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and pro... by Kimberly D. Mackenzie, Mario Ortega, Yoel Kessler, Verena Ramirez Campos, Lynda J. Krasenbaum, Karen Carr, Xiaoping Ning, Jennifer Stratton

    Published 2022-11-01
    Get full text
    Article
  5. 5
    Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States

    Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States by Peter McAllister, Lois Lamerato, Lynda J. Krasenbaum, Joshua M. Cohen, Krishna Tangirala, Stephen Thompson, Maurice Driessen, Julian Casciano, Zenobia Dotiwala, Alexander Mauskop

    Published 2021-12-01
    Get full text
    Article
  6. 6
    Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

    Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, pla... by Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl

    Published 2022-05-01
    Get full text
    Article
  7. 7
    Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

    Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-control... by Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl

    Published 2021-11-01
    Get full text
    Article

Search Tools: